Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab in active non-radiographic axial spondyloarthritis
NCT06860750Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-radiographic axial spondyloarthritis (nr-axSpA) comparing SHR-1314 with Placebo -> SHR-1314 (2 arms). Primary endpoint: Assessment of SpondyloArthritis international Society 40 Response at 16 weeks. Started Apr 2025; status: recruiting.
02
Drugs
vunakizumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT06860750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860750.